QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:LMAT

LeMaitre Vascular - LMAT Stock Forecast, Price & News

$54.51
-1.48 (-2.64%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$53.34
$55.76
50-Day Range
$42.02
$55.99
52-Week Range
$38.32
$60.79
Volume
132,964 shs
Average Volume
114,758 shs
Market Capitalization
$1.20 billion
P/E Ratio
53.97
Dividend Yield
0.89%
Price Target
$60.00

LeMaitre Vascular MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
10.1% Upside
$60.00 Price Target
Short Interest
Bearish
7.41% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
0.45mentions of LeMaitre Vascular in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$3.17 M Sold Last Quarter
Proj. Earnings Growth
14.66%
From $1.16 to $1.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

523rd out of 1,124 stocks

Surgical & Medical Instruments Industry

50th out of 113 stocks

LMAT stock logo

About LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LeMaitre Vascular Stock Performance

LMAT traded down $1.48 on Tuesday, hitting $54.51. 132,964 shares of the company were exchanged, compared to its average volume of 114,758. The firm has a fifty day simple moving average of $47.56 and a two-hundred day simple moving average of $45.66. LeMaitre Vascular has a 12 month low of $38.32 and a 12 month high of $60.79. The stock has a market capitalization of $1.20 billion, a PE ratio of 55.44, a price-to-earnings-growth ratio of 4.73 and a beta of 1.21.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 8th. Shareholders of record on Thursday, August 25th will be issued a $0.125 dividend. This represents a $0.50 annualized dividend and a yield of 0.92%. The ex-dividend date is Wednesday, August 24th. LeMaitre Vascular's dividend payout ratio (DPR) is currently 49.51%.

Wall Street Analysts Forecast Growth

Separately, Barrington Research reduced their price target on LeMaitre Vascular from $54.00 to $50.00 in a research report on Friday, April 29th.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 21,348 shares of the stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $54.97, for a total value of $1,173,499.56. Following the completion of the sale, the chief executive officer now owns 2,544,760 shares in the company, valued at approximately $139,885,457.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CEO George W. Lemaitre sold 17,702 shares of the firm's stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $55.89, for a total value of $989,364.78. Following the completion of the transaction, the chief executive officer now owns 2,507,476 shares in the company, valued at approximately $140,142,833.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO George W. Lemaitre sold 21,348 shares of the firm's stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $54.97, for a total value of $1,173,499.56. Following the completion of the transaction, the chief executive officer now owns 2,544,760 shares of the company's stock, valued at approximately $139,885,457.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 57,743 shares of company stock worth $3,172,099. 12.50% of the stock is currently owned by company insiders.

Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

LMAT Stock News Headlines

LeMaitre Vascular (LMAT) Lags Q2 Earnings Estimates
LeMaitre Q2 2022 Financial Results
Barrington Remains a Buy on Lemaitre Vascular (LMAT)
Lemaitre Vascular Misses Q1 EPS by 1c
LeMaitre Q1 2022 Financial Results
See More Headlines
Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

LMAT Company Calendar

Last Earnings
10/28/2021
Ex-Dividend for 6/2 Dividend
5/16/2022
Dividend Payable
6/02/2022
Today
8/16/2022
Ex-Dividend for 9/8 Dividend
8/24/2022
Dividend Payable
9/08/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LMAT
Employees
450
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$60.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+10.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$26.91 million
Pretax Margin
18.73%

Debt

Sales & Book Value

Annual Sales
$154.42 million
Cash Flow
$1.73 per share
Book Value
$11.64 per share

Miscellaneous

Free Float
19,218,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
1.21

Social Links















LMAT Stock - Frequently Asked Questions

Should I buy or sell LeMaitre Vascular stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LMAT shares.
View LMAT analyst ratings
or view top-rated stocks.

What is LeMaitre Vascular's stock price forecast for 2022?

1 brokerages have issued twelve-month target prices for LeMaitre Vascular's shares. Their LMAT share price forecasts range from $50.00 to $70.00. On average, they predict the company's share price to reach $60.00 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts price targets for LMAT
or view top-rated stocks among Wall Street analysts.

How have LMAT shares performed in 2022?

LeMaitre Vascular's stock was trading at $50.23 at the beginning of 2022. Since then, LMAT shares have increased by 8.5% and is now trading at $54.51.
View the best growth stocks for 2022 here
.

When is LeMaitre Vascular's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our LMAT earnings forecast
.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) posted its quarterly earnings data on Thursday, October, 28th. The medical instruments supplier reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by $0.03. The medical instruments supplier earned $38.37 million during the quarter, compared to the consensus estimate of $39.05 million. LeMaitre Vascular had a net margin of 13.94% and a trailing twelve-month return on equity of 9.86%. The company's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.37 EPS.

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular declared a quarterly dividend on Tuesday, July 26th. Investors of record on Thursday, August 25th will be paid a dividend of $0.125 per share on Thursday, September 8th. This represents a $0.50 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Wednesday, August 24th.
Read our dividend analysis for LMAT
.

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular (NASDAQ:LMAT) pays an annual dividend of $0.50 per share and currently has a dividend yield of 0.89%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 49.51%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LMAT will have a dividend payout ratio of 37.59% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LMAT.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular updated its third quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $0.24-$0.29 for the period, compared to the consensus estimate of $0.31. The company issued revenue guidance of $39.00 million-$41.00 million, compared to the consensus revenue estimate of $40.16 million.

What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular Chief Executive Officer George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among the company's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and Salesforce (CRM).

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Conestoga Capital Advisors LLC (8.45%), Copeland Capital Management LLC (5.52%), Geneva Capital Management LLC (3.90%), State Street Corp (3.43%), Russell Investments Group Ltd. (1.61%) and Voya Investment Management LLC (1.58%). Insiders that own company stock include David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends
.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $54.51.

How much money does LeMaitre Vascular make?

LeMaitre Vascular (NASDAQ:LMAT) has a market capitalization of $1.20 billion and generates $154.42 million in revenue each year. The medical instruments supplier earns $26.91 million in net income (profit) each year or $1.01 on an earnings per share basis.

How many employees does LeMaitre Vascular have?

The company employs 450 workers across the globe.

Does LeMaitre Vascular have any subsidiaries?
The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.
Read More
When was LeMaitre Vascular founded?

LeMaitre Vascular was founded in 1983.

How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The official website for the company is www.lemaitre.com. The medical instruments supplier can be reached via phone at (781) 221-2266 or via fax at 781-425-5049.

This page (NASDAQ:LMAT) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.